Biomarkers for the effects of antipsychotic drugs in healthy volunteers

British Journal of Clinical Pharmacology

Volumn 51, Issue 2, 2001, Pages 119-132

  De Visser, S J ^a   Van der Post, J ^a   Pieters, M S M ^a   Cohen, A F ^a   Van Gerven, J M A ^a  

^a CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

Author keywords

Antipsychotic; Biomarker; Cognition; Phase I; Prolactin

Indexed keywords

AMISULPRIDE; CHLORPROMAZINE; CLOZAPINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; FLUPHENAZINE; HALOPERIDOL; MAZAPERTINE; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PIMOZIDE; PLACEBO; PROCHLORPERAZINE; PROLACTIN; RACLOPRIDE; REMOXIPRIDE; RISPERIDONE; SETOPERONE; SULPIRIDE; THIETHYLPERAZINE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE; ZETIDOLINE; ZOTEPINE;

ALERTNESS; ARTICLE; COGNITION; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG TOLERABILITY; HUMAN; MEDICAL INFORMATION; MOTOR PERFORMANCE; NEUROPSYCHOLOGICAL TEST; PATHOGENESIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROLACTIN RELEASE; PSYCHOPHARMACOLOGY; SACCADIC EYE MOVEMENT; STATISTICAL ANALYSIS; VISUOMOTOR COORDINATION;

ANTIPSYCHOTIC AGENTS; BIOLOGICAL MARKERS; CLINICAL TRIALS, PHASE I; EYE MOVEMENTS; HUMANS; MOTOR ACTIVITY; PROLACTIN;

EID: 0035101130     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2001.01308.x     Document Type: Article

References (112)

1. A phase-overlapping anhedonia-model (animal-volunteer-patient) to predict the effects of neuroleptics
2. Haloperidol enhances latent inhibition in visual tasks in healthy people
3. Event-related potentials in schizotypal personality disorder
4. The Maudsley Family Study, II. Endogenous event-related potentials in familial schizophrenia
5. The action of sedatives on brain stem oculomotor systems in man
6. The use of analogue scales in rating subjective feelings
7. Selected quantitative EEG (QEEG) and event-related potential (ERP) variables as discriminators for positive and negative schizophrenia
8. Pharmaco-EEG profile of levoprotiline: Second example to discuss the predictive value of pharmaco-electroencephalography in early human pharmacological evaluations of psychoactive drugs
9. Electroencephalographic characterization of brain dopaminergic stimulation by apomorphine in healthy volunteers
10. Predictive value of pharmaco-electroencephalography in early human-pharmacological evaluations of psychoactive drugs. First example: Savoxepine
11. Pharmaco-EEG profile of Maroxepine: Third example to discuss the predictive value of pharmaco-electroencephalography in early human pharmacological evaluations of psychoactive drugs
12. Benzodiazepines impair smooth pursuit eye movements
13. A microcomputer based system for recording and analysis of smooth pursuit and saccadic eye movements
14. A selective review of biological markers in schizophrenia
15. Psychomotor impairment and cognitive disturbances induced by neuroleptics
16. Guidelines for the use of antipsychotic. Drug studies in healthy volunteers
17. A comparison of the sensitivities of adaptive tracking, eye movement analysis and visual analog lines to the effects of incremental doses of temazepam in healthy volunteers
18. Effects of temazepam on saccadic eye movements: Concentration-effect relationships in individual volunteers
19. The sensitivity of pharmacodynamic tests for the central nervous system effects of drugs on the effects of sleep deprivation
20. A pharmacodynamic Markov mixed-effect model for temazepam's effect on sleep
21. P300 subcomponents reflect different aspects of psychopathology in schizophrenia
22. More choices for treating voices
23. Aandacht, bewustzijn en psychofarmaca
24. Event-related and motor responses to probes in a forewarned reaction time task in schizophrenic patients
25. ERP abnormalities during semantic processing in schizophrenia
26. Event-related potentials in schizophrenia: Their biological and clinical correlates and a new model of schizophrenic pathophysiology
27. P300 in first degree relatives of schizophrenics
28. Brain potential evidence for an auditory sensory memory deficit in schizophrenia
29. Auditory P300 and eye tracking dysfunction in schizophrenic pedigrees
30. Correlation of auditory 'oddball' P300 with verbal memory deficits in schizophrenia
31. Neuropsychological and P300 abnormalities in schizophrenics and their relatives
32. Use of neuroendocrine techniques in psychopharmacological research
33. Prolactin responses to neuroleptic drugs: An approach to the study of brain dopamine blockade in humans
34. Strategies of neuroendocrine research in psychiatry
35. Dopamine receptor agonists: Mechanisms underlying autoreceptor selectivity. II. Theoretical considerations
36. Dopamine autoreceptor stimulation: Clinical significance
37. Neuroendocrine tests during treatment with neuroleptic drugs I. Plasma prolactin response to haloperidol challenge
38. Hyperprolactinaemia induced by risperidone
39. Hyperprolactinaemia associated with effective antipsychotic treatment no longer inevitable
40. Increased brain dopamine and dopamine receptors in schizophrenia
41. Dopamine receptors, antipsychotic action and schizophrenia
42. Dopamine receptors and schizophrenia: Contribution of molecular genetics and clinical neuropsychology
43. The prolactin response to neuroleptic drugs. A test of dopaminergic blockade: Neuroendocrine studies in normal men
44. Prolactin responses to neuroleptics in normal and schizophrenic subjects
45. 2 receptors
46. Effects of psychotropic drugs (desimipramine, chlorimipramine, sulpiride and diazepam) on the human HPA axis
47. Effect of fenfluramine on episodic ACTH and cortisol secretion
48. A comparison of the neuro-endocrinological and temperature effects of DU 29894, flesinoxan, sulpiride and haloperidol in normal volunteers
49. Single dose human pharmacology of umespirone
50. Hormonal probes of central serotonergic activity: Do they really exist?
51. Haloperidol and cognitive shifting
52. Effect of haloperidol on nicotine-induced enhancement of vigilance in human subjects
53. The effect of neuroleptics on cognitive and psychomotor function. A preliminary study in healthy volunteers
54. Remoxipride versus haloperidol in healthy volunteers: Psychometric performance and subjective tolerance profiles
55. A cognitive-neuroscience approach for elucidation of mechanisms underlying temporal information processing
56. Effects of haloperidol and amisulpride on motor and cognitive skill learning in healthy volunteers
57. A comparison of the central nervous system effects of haloperidol, chlorpromazine and sulpiride in normal volunteers
58. Psychomotor, respiratory and neuroendocrinological effects of nalbuphine and haloperidol, alone and in combination, in healthy subjects
59. Intravenous administration of haloperidol to healthy volunteers: Lack of subjective effects but clear objective effects
60. Central nervous system noradrenergic and dopaminergic turnover in response to acute neuroleptic challenge
61. Suppression of HPA-axis activity by haloperidol after experimentally induced heat stress
62. Effects of granisetron and haloperidol, alone and in combination, on psychometric performance and the EEG
63. Differential effects of clonidine, haloperidol, diazepam and tryptophan depletion on focused attention and attentional search
64. Is there a common dopaminergic basis of time perception and reaction time?
65. Dopaminergic and serotoninergic influence on duration discrimination and vigilance
66. Determination of pharmacodynamics of the new neuroleptic zetidoline by neuroendocrinologic, pharmaco-EEG, and psychometric studies - Part I
67. Spontaneous motor activity in healthy volunteers after single doses of haloperidol
68. Incremental dosage of the new antipsychotic mazapertine induces tolerance to cardiovascular and cognitive effects in healthy men
69. Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans
70. Determination of pharmacodynamics of the new neuroleptic zetidoline by neuroendocrinologic, pharmaco-EEG, and psychometric studies: Part II
71. On dopaminergic modulation of temporal information processing
72. Effect of haloperidol on a symbol digit substitution task in normal adult males
73. The effects of remoxipride and chlorpromazine on eye movements and psychomotor performance in healthy volunteers
74. Effects of psychotropic drugs on digit substitution: Comparison of the computerized symbol-digit substitution and traditional digit-symbol substitution tests
75. Olanzapine. Interaction study with imipramine
76. The psychomotor effects of paroxetine alone and in combination with haloperidol, amylobarbitone, oxazepam, or alcohol
77. Effect of the dopamine receptor blocking agent pimozide on the growth hormone response to arginine and exercise and on spontaneous growth hormone fluctuations
78. Acute antagonism of dopamine D2-like receptors by amisulpride: Effects on hormone secretion in healthy volunteers
79. Effects of acute administration of zetidoline, a new antidopaminergic drug, on plasma prolactin and aldosterone levels in man
80. Effects of remoxipride on psychomotor performance, alone and in combination with ethanol and diazepam
81. The comparison of the effects of DL-308, a potential new neuroleptic agent, and thioridazine on some psychological and physiological functions in healthy volunteers
82. Remoxipride - A new potential antipsychotic drug. Pharmacological effects and pharmacokinetics following repeated oral administration in male volunteers
83. Effects of remoxipride on measures of psychological performance in healthy volunteers
84. Neuroendocrine responses to single oral doses of remoxipride and sulpiride in healthy female and male volunteers
85. Effect of the dopamine D2 antagonist sulpiride on event-related potentials and its relation to the law of initial value
86. A comparison of the effects of olanzapine, haloperidol and placebo on cognitive and psychomotor functions in healthy elderly volunteers
87. Effect of sulpiride on vigilance in healthy subjects
88. Psychomotor, cognitive, extrapyramidal, and affective functions of healthy volunteers during treatment with an atypical (amisulpride) and a classic (haloperidol) antipsychotic
89. Single oral dose kinetics of zotepine and its relationship to prolactin response and side effects
90. The effects of chlorpromazine and lorazepam on abnormal antisaccade and no-saccade distractibility
91. Thioridazine dose-related effects on biomechanical force platform measures of sway in young and old men
92. The effects of sulpiride on psychomotor performance and subjective tolerance
93. Antipsychotic drug effects in a model of schizophrenic attentional disorder: A randomized controlled trial of the effects of haloperidol on latent inhibition in healthy people
94. The new selective D2-dopamine receptor antagonist raclopride - Pharmacokinetics, safety and tolerability in healthy males
95. Multilead quantitative EEG profile of clozapine in resting and vigilance-controlled conditions
96. Neuroendocrine effects of setoperone: A new neuroleptic drug
97. Electroencephalographic and psychomotor effects of chlorpromazine and risperidone relative to placebo in healthy volunteers
98. Influence of rate of administration of raclopride on akathisia and prolactin response
99. A comparison of some psychological and physiological effects exerted by zetidoline (DL308) and by oxazepam
100. Remoxipride - A new potential antipsychotic compound. Tolerability and pharmacokinetics after single oral and intravenous administration in healthy male volunteers
101. Pharmacokinetics of raclopride formulations. Influence of prolactin and tolerability in healthy male volunteers
102. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects
103. Comparative placebo-controlled pharmacodynamic studies with zotepine and clozapine utilizing pharmaco-EEG and psychometry
104. Effects of the dopamine-related drug bromocriptine on event-related potentials and its relation to the law of initial value
105. Psychopharmacological correlates of post-psychotic depression: A double-blind investigation of haloperidol vs thiothixene in outpatient schizophrenia
106. The cerebral cortex: A case for a common site of action of antipsychotics
107. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values
108. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence